Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Carboplatin
Radiation: Proton Radiotherapy
Drug: Paclitaxel

First Posted Date: 2007-07-02

Last Posted Date: 2019-02-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 84

Registration Number: NCT00495170

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Head and Neck Squamous Cell Carcinoma
Metastatic Squamous Cell Carcinoma of the Larynx
Metastatic Squamous Cell Carcinoma of the Oral Cavity
Metastatic Squamous Cell Carcinoma of the Oropharynx
Recurrent Oropharyngeal Squamous Cell Carcinoma
Metastatic Squamous Cell Carcinoma of the Hypopharynx
Recurrent Head and Neck Squamous Cell Carcinoma
Recurrent Hypopharyngeal Squamous Cell Carcinoma
Recurrent Laryngeal Squamous Cell Carcinoma
Recurrent Oral Cavity Squamous Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Sorafenib

First Posted Date: 2007-06-29

Last Posted Date: 2024-12-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT00494182

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC)

Phase 2

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: carboplatin
Procedure: radiotherapy

First Posted Date: 2007-06-29

Last Posted Date: 2009-11-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 4

Registration Number: NCT00494026

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wolverhampton, West Midlands, United Kingdom

Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas

Phase 2

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2007-06-27

Last Posted Date: 2014-01-10

Lead Sponsor: San Diego Pacific Oncology & Hematology Associates

Target Recruit Count: 80

Registration Number: NCT00492687

Locations: 🇺🇸
San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas, Encinitas, California, United States

Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer

Phase 2

Completed

Conditions: Epithelial Ovarian Cancer

First Posted Date: 2007-06-25

Last Posted Date: 2007-06-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 7

Registration Number: NCT00490711

Locations: 🇸🇰
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bratislava, Slovakia

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

Phase 1

Completed

Conditions: Extrahepatic Bile Duct Cancer
Gallbladder Cancer
Gastric Cancer
Liver Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: capecitabine
Drug: carboplatin
Drug: epirubicin hydrochloride
Genetic: microarray analysis
Genetic: polymorphism analysis
Other: pharmacological study

First Posted Date: 2007-06-14

Last Posted Date: 2024-01-03

Lead Sponsor: University of Nebraska

Target Recruit Count: 46

Registration Number: NCT00486356

Locations: 🇺🇸
University of Nebraska Medical Center, Eppley Cancer Center, Omaha, Nebraska, United States

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Phase 3

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2007-06-07

Last Posted Date: 2013-08-12

Lead Sponsor: Medical Research Council

Target Recruit Count: 1520

Registration Number: NCT00483782

Locations: 🇦🇺
Cancer Therapy Centre at Liverpool Hospital, Liverpool, New South Wales, Australia
🇬🇧
St. George's Hospital, London, England, United Kingdom
🇬🇧
Portsmouth Oncology Centre at Saint Mary's Hospital, Portsmouth Hants, England, United Kingdom

and more 139 locations

Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Cisplatin
Drug: carboplatin

First Posted Date: 2007-06-06

Last Posted Date: 2017-08-25

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 86

Registration Number: NCT00483223

Locations: 🇺🇸
University of Alabama-Birmingham, Birmingham, Alabama, United States
🇺🇸
UCSF, San Francisco, California, United States
🇺🇸
Johns Hopkins University Medical Center, Baltimore, Maryland, United States

and more 7 locations

A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer

Phase 1

Completed

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: carboplatin
Drug: cisplatin
Radiation: radiation therapy

First Posted Date: 2007-06-04

Last Posted Date: 2012-11-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 120

Registration Number: NCT00482014

Locations: 🇮🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India

Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: vorinostat
Drug: paclitaxel
Drug: carboplatin
Other: placebo
Other: laboratory biomarker analysis

First Posted Date: 2007-06-01

Last Posted Date: 2014-10-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 94

Registration Number: NCT00481078

Locations: 🇺🇸
City of Hope, Duarte, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy